Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | MediciNova, AnnJi Pharma, EA Pharma, Aptinyx, Toray, Solasia Pharma, Enveric

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chemotherapy-Induced Peripheral Neuropathy Therapeutics Market.

The report provides a detailed description of the Chemotherapy-Induced Peripheral Neuropathy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Chemotherapy-Induced Peripheral Neuropathy Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Chemotherapy-Induced Peripheral Neuropathy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy-Induced Peripheral Neuropathy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Chemotherapy-Induced Peripheral Neuropathy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Chemotherapy-Induced Peripheral Neuropathy treatment market.

Learn More about the Clinical and Commercial Development Activities in the Chemotherapy-Induced Peripheral Neuropathy Therapeutics Domain @
https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Chemotherapy Induced Peripheral Neuropathy (CIPN). Currently, MediciNova is leading the therapeutics market with its Chemotherapy Induced Peripheral Neuropathy (CIPN) drug candidates in the most advanced stage of clinical development.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Companies in the Therapeutics Market Include:
• MediciNova
• Asahi Kasei Pharma Corp.
• AnnJi Pharmaceutical
• EA Pharma
• Aptinyx
• Sonnet Biotherapeutics Holdings
• Toray
• Solasia Pharma
• Enveric Biosciences
• Regenacy Pharmaceuticals
• NeuroBo Pharmaceuticals
And Many Others

Emerging and Marketed Chemotherapy-Induced Peripheral Neuropathy (CIPN) Therapies Covered in the Report Include:
• MN-166 (ibudilast): MediciNova
• ART-123: Asahi Kasei Pharma Corp.
• HALNEURON (TETRODOTOXIN or TTX): WEX Pharmaceuticals
• ATX01: AlgoTx
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Chemotherapy-Induced Peripheral Neuropathy Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Chemotherapy-Induced Peripheral Neuropathy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Chemotherapy-Induced Peripheral Neuropathy Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Chemotherapy-Induced Peripheral Neuropathy Current Treatment Patterns
4. Chemotherapy-Induced Peripheral Neuropathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chemotherapy-Induced Peripheral Neuropathy Late-Stage Products (Phase-III)
7. Chemotherapy-Induced Peripheral Neuropathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chemotherapy-Induced Peripheral Neuropathy Discontinued Products
13. Chemotherapy-Induced Peripheral Neuropathy Product Profiles
14. Chemotherapy-Induced Peripheral Neuropathy Companies
15. Chemotherapy-Induced Peripheral Neuropathy Drugs
16. Dormant and Discontinued Products
17. Chemotherapy-Induced Peripheral Neuropathy Unmet Needs
18. Chemotherapy-Induced Peripheral Neuropathy Future Perspectives
19. Chemotherapy-Induced Peripheral Neuropathy Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.